What Is Stomach Cancer (Gastric Carcinoma)?

Stomach Cancer (Gastric Carcinoma) refers to the growth of malignant cells within the stomach lining. Often beginning subtly, it gradually advances, affecting deeper tissues and altering normal stomach functions. To effectively confront it, understanding its basic biology is essential.

Biological Basis: Exploring Cancer Cell Metabolism

One hallmark of cancer cells, including those of gastric carcinoma, is their abnormal metabolic processes. Unlike normal cells primarily using oxidative phosphorylation, cancer cells heavily employ aerobic glycolysis—a phenomenon known as the Warburg effect.

Cancer cells consume glucose at approximately 200 times the rate of normal cells.
This metabolic dependency offers therapeutic avenues targeting glycolysis through novel HK Metabolic Therapy approaches.

Prevalence and Regional Impact in Hong Kong and Asia

Gastric carcinoma is globally significant, particularly in Asia. According to WHO estimates for 2024, approximately one million new cases surface annually, the majority located across Asian regions, including China, Korea, Japan, and Hong Kong. In Hong Kong specifically, gastric carcinoma stands as one of the top cancers, with increasing concern due to shifting dietary and lifestyle factors.

Affected Populations: Risks and Demographics

Age Factor: Most cases diagnosed are individuals aged 55 and above.
Gender Factor: Men are approximately twice as likely to develop gastric carcinoma compared to women.
Genetic Risks: Family history significantly increases risk.
Diet and Environmental Risks: Diets high in salty, smoked, or preserved foods prevalent in parts of Asia significantly elevate risk.

Emotionally, patients face immense psychological burdens due to fear and uncertainty about prognosis; physically, symptoms such as persistent stomach pain, weight loss, nausea, and fatigue disrupt daily life profoundly.

Causes and Risk Factors of Stomach Cancer (Gastric Carcinoma)

Genetic Factors Influencing Gastric Cancer Risk

Several genetic predispositions significantly increase the likelihood of developing gastric carcinoma. Inherited mutations, such as those found in CDH1 gene (linked specifically to hereditary diffuse gastric carcinoma), notably escalate risks.

Inherited CDH1 mutations translate to an approximate 70% lifetime gastric carcinoma risk.
APC and TP53 genetic mutations also demonstrate profound impacts on cancer development.

Metabolic Vulnerabilities: Exploiting Cancer’s Achilles Heel

Metabolic distinctiveness of carcinoma cells extends beyond glucose metabolism. About 50% of gastric cancer cells distinctly depend on glutamine for nucleotide synthesis, rendering them vulnerable to metabolic interventions targeting glutamine dependency pathways, illuminating promising therapeutic strategies.

Lifestyle and Environmental Factors

Several modifiable lifestyle factors prominently determine gastric carcinoma risks. These particularly include:

Dietary Habits: Regular consumption of salty, smoked, or processed meats significantly accelerates gastric carcinoma development due to carcinogenic compounds.
Tobacco and Alcohol: Frequent tobacco use multiplies gastric carcinoma probability nearly twofold. Alcohol intake, particularly exceeding moderate levels, similarly amplifies risk.
Obesity: Excessive body weight often correlates with gastric carcinoma, mainly affecting the upper portion of the stomach (cardia region).

Infectious Causes Specific to Hong Kong and Asia

A critical regional feature is the influential role infectious pathogens play in elevating gastric carcinoma incidence. Particularly notable is Helicobacter pylori infection, prevalent in approximately 60% of adults across Asian populations.

Chronic Helicobacter pylori infection significantly heightens gastric carcinoma risks by triggering long-standing inflammation.
Epstein-Barr Virus (EBV) infection also associates with specific gastric carcinoma subtypes in Asia.

Raising Awareness, Screening, and Early Intervention

Early screening and detection drastically enhance prognosis. Regular endoscopic screening for high-risk groups—those over 50, smokers, frequent drinkers, and those with familial cancer histories—is crucial. Public education campaigns promoting healthier diets and lifestyles contribute positively toward reducing gastric carcinoma prevalence in Hong Kong and Asian regions.

At AllCancer, leveraging Nobel-prize-winning research (Prof. James P. Allison and Prof. Gregg Semenza), and our pioneering achievements (global patents, FDA certifications), we provide personalized treatments utilizing novel metabolic therapies that significantly boost therapeutic efficacy, including the groundbreaking HK-4D Metabolic Therapy.

Explore the benefits and proven outcomes of our unique HK-4D Metabolic Therapy approach designed specifically for Gastric Carcinoma. Discover the power of metabolism-targeted therapies transforming patient outcomes today—“Discover how 4D Therapy transforms Stomach Cancer (Gastric Carcinoma) treatment”.

Your journey toward recovery begins with knowledge and action. Book your personalized consultation with AllCancer specialists today and uncover how targeted metabolic oncology therapies can offer renewed hope and healing avenues for Gastric Carcinoma patients and families in Hong Kong and beyond.

Take inspiration from our past patients, such as Jane, who bravely faced Stage 4 cancer with profound courage and successfully benefited via our groundbreaking treatments. Her journey illustrates how cutting-edge therapies combined with compassion and personalized care can change the course of gastric carcinoma and enrich patients’ lives.

Symptoms of Stomach Cancer (Gastric Carcinoma)

Being able to recognize the symptoms of Stomach Cancer (Gastric Carcinoma) early can significantly improve outcomes and prognosis. While the symptoms may initially appear mild or nonspecific, they tend to become more pronounced as the cancer advances. Understanding and promptly acting upon these signs can be life-saving.

Common Early Symptoms:

Persistent indigestion and stomach discomfort
Mild abdominal pain or vague discomfort, particularly after eating
Bloating or a sense of fullness after consuming small amounts of food
Nausea or occasional vomiting
Reduced appetite or unexplained loss of interest in food
General fatigue and unexplained weakness
Mild heartburn symptoms resistant to regular treatment

Symptoms Indicative of Advanced Disease:

Severe weight loss without intentional dietary changes
Difficulty swallowing (dysphagia)
Persistent abdominal pain, intensifying over time
Vomiting blood or material that resembles coffee grounds (hematemesis)
Passing dark, tar-like stools (melena) indicating gastrointestinal bleeding
Anemia symptoms such as paleness and fatigue due to chronic blood loss
Discovery of a palpable lump or fullness in the abdomen, indicating a larger tumor
Jaundice (yellowing of skin and eyes) in rare cases associated with liver metastasis

It’s important to understand that many people experience these symptoms due to other less serious digestive conditions. Nevertheless, persistent or worsening symptoms should prompt immediate medical evaluation.

How Symptoms Reflect Tumor Biology:

Symptoms of Stomach Cancer often stem from the tumor affecting digestive processes, such as obstruction or alteration of normal gastric emptying. Tumors can disrupt the stomach’s lining, causing bleeding and chronic inflammation. The biological mechanism behind such symptoms involves rapid cancer cell growth driven by heightened glucose metabolism (Warburg effect), extensively proven in studies (e.g., Semenza’s Nobel Prize-winning discovery). Therefore, recognizing the biological underpinnings helps patients understand the progression of symptoms.

Early evaluation and intervention are critical. If you experience ongoing symptoms mentioned earlier, booking a diagnostic evaluation through our state-of-the-art Center for Cancer Diagnostics can significantly improve your outcomes.

Stages of Stomach Cancer (Gastric Carcinoma) and Survival Rates

Diagnosing the stage of Stomach Cancer (Gastric Carcinoma) is fundamental for establishing prognosis, treatment planning, and predicting survival rates. Staging follows internationally accepted criteria, with data specifically calibrated for Asian populations, enabling tailored patient management in regions like Hong Kong and greater Asia.

Stage 1 – Stomach Cancer (Gastric Carcinoma)

Stage 1 Stomach Cancer is characterized mainly by a localized tumor within the mucosal or submucosal layers of the stomach. Tumors are typically small and confined, with a very limited extent of invasion.

Typical tumor size: less than 3 centimeters
No involvement of lymph nodes or distant metastasis

Primary treatment options at this stage:

Endoscopic mucosal resection (EMR)
Gastrectomy (partial surgical removal of the stomach)
Radiotherapy in selected cases

Survival data (Hong Kong):

5-year survival rate exceeding 90%

Stage 2 – Stomach Cancer (Gastric Carcinoma)

Stage 2 represents a critical advancement, characterized by tumor invasion into deeper muscular layers or the early involvement of nearby lymph nodes.

Typical tumor size: 3-6 centimeters or deeper invasion into muscle layers
Limited lymph node involvement (1-6 nodes)

Treatment strategies typically escalate to include:

Surgery (gastrectomy with lymphadenectomy)
Adjuvant or neoadjuvant chemotherapy
Targeted radiation therapy

Survival data (Asia-specific):

5-year relative survival rate: approximately 70-85%

Stage 3 – Stomach Cancer (Gastric Carcinoma)

Stage 3 indicates significant disease progression, with tumor spreading through the stomach layers and extensive lymph node involvement.

Tumor invasion into outer stomach layers (serosa) or surrounding tissues
Regional lymph nodes heavily involved (7-15 nodes)
No distant metastasis observed

Multi-modal therapeutic approach:

Radical gastrectomy with extensive lymph node dissection
Systemic chemotherapy as standard care
Metabolic therapies targeting cancer’s nutritional vulnerabilities

Survival data (Hong Kong & Asia):

50–70% 5-year relative survival rate

Stage 4 – Stomach Cancer (Gastric Carcinoma)

Stage 4 gastric carcinoma represents metastatic disease, characterized by cancer spreading to distant organs such as the liver, lungs, peritoneum, and lymph nodes far from the stomach.

Distant metastases present
Significant health deterioration and lower performance status
Challenging to treat effectively due to systemic involvement

Advanced therapeutic interventions include:

Systemic chemotherapy and immunotherapy combinations
Metabolic and palliative therapies for chronic disease management prospects

Survival expectation data (Asian demographics):

Approximate 5-year survival: 5-20%

Despite challenges, research from AllCancer’s Nobel laureate-backed 4D Therapy suggests promising potential for turning advanced gastric carcinoma into a manageable chronic condition.

Limitations of Traditional Therapies for Stomach Cancer (Gastric Carcinoma)

Challenges Associated with Chemotherapy

Chemotherapy remains one of the most commonly employed conventional approaches to treat Stomach Cancer (Gastric Carcinoma). While chemotherapy can shrink tumors and temporarily improve patient outcomes, it brings substantial side effects that compromise patient quality of life. According to recent oncology data from Hong Kong and other Asian regions, approximately 78% of patients undergoing chemotherapy experience severe bone marrow suppression, leading to significantly reduced blood cell counts. This side effect heightens the risk of secondary infections and can necessitate blood transfusions, introducing additional medical complexities and burdens for patients and caregivers alike.

Further complicating chemotherapy use is the high incidence of cardiac toxicity, occurring in approximately 23% of treated individuals, per recent JAMA Oncology (2023) statistics. Cardiotoxicity can result in debilitating symptoms, including cardiac arrhythmias, congestive heart failure, or even cardiac arrest. Consequently, treatment often requires monitoring and dose adjustments, typically diminishing therapeutic effectiveness and necessitating a delicate balance between cancer delivery and tolerability.

Bone Marrow Suppression (78% incidence)
Cardiac Toxicity (23% incidence)
Nausea & Vomiting (>60% incidence)
Secondary Infection Risk (~54%)

Radiation Therapy Side Effects and Limitations

Radiation therapy aims to kill malignant cells by damaging their DNA, briefly halting tumor growth. However, in treating gastric carcinoma, radiation closely associated with substantial collateral tissue damage. Both normal stomach tissues and adjacent structures such as intestines, liver, and kidneys can be inadvertently affected, often resulting in secondarily debilitating health consequences. Side effects commonly include:

Severe fatigue and weakness, reducing patient mobility
Gastrointestinal ulceration and internal bleeding
Kidney and liver impairment due to adjacent organ exposure
Risk of radiation-induced secondary cancers increased by as much as 300%, noted by a significant JAMA Oncology (2023) publication.

For Asian patients, particularly given genetic predispositions and higher baseline risk for certain malignancies due to regional dietary and environmental factors, these radiation-associated risks are even more pronounced. Asian-specific genetic variations might further exacerbate vulnerability to radiation-associated tissue damage, significantly limiting this treatment approach’s overall feasibility, especially in recurrent or late-stage cases.

Risks and Limitations of Surgical Approaches

While surgical intervention remains a cornerstone in the early management of gastric cancer, its feasibility reduces drastically as disease progresses. Late-stage Stomach Cancer (Gastric Carcinoma) exhibits often infiltrative and metastatic tendencies, greatly diminishing the success rate and safety of surgical resection. The risks inherent to surgery — including severe infections, hemorrhage, blood clot formation, and complications from anesthesia — regularly pose additional concerns, especially given the older patient demographic commonly observed with gastric carcinoma in Hong Kong and Asia.

Post-operative infections (~17% of patients)
Internal bleeding and hemorrhage (12%)
Anesthetic-related complications in elderly Asian populations (increased by ~25%)
Post-surgical quality-of-life impairments (common and profoundly influencing nutrition, digestion, and overall wellbeing)

Low Efficacy in Late-stage Stomach Cancer Cases

Crucially, traditional cancer therapies possess limited efficacy in treating metastatic and advanced gastric cancer stages. Objective response rates (ORR) in chemotherapy regimens for metastatic Stomach Cancer (Gastric Carcinoma) rarely exceed 21%. This low success rate underpins a grim prognosis and a significant unmet medical need, especially in advanced regional clinical practice settings across Hong Kong and Asia. Furthermore, metastatic cancers often develop resistance to conventional chemotherapeutic agents, severely restricting treatment options and hindering clinical outcomes.

Metabolic resistance mechanisms play a central role in traditional therapy shortcomings. Gastric cancer cells demonstrate up to a 400% elevation in DNA repair enzyme activity compared to normal tissues. Such heightened DNA repair mechanisms greatly reduce chemotherapy agents and radiation therapies’ efficacy, prompting therapeutic resistance and swiftly progressing disease recurrence, notably seen in Asian populations where genetic diversity and aggressive disease phenotypes have significant impacts.

Psychosocial and Quality-of-Life Challenges

Aside from clinical limitations, conventional treatments pose emotional difficulties, burdening patients psychologically and socially. Chronic fatigue caused by chemotherapy and radiation reduces functional independence, causing considerable emotional distress and negatively impacting family and caregiver dynamics. The overall burden of gastric cancer and its arduous traditional treatments can lead to psychological disorders such as anxiety, depression, or even post-traumatic stress disorder (PTSD), documented increasingly by recent surveys in Hong Kong-based oncology clinics.

The necessity and value of more humane and advanced treatments become apparent when considering psychosocial impacts. The limitation of traditional therapies extends beyond mere physiological parameters, influencing holistic patient wellness and their families/social circles.

Urgent Need for New and Improved Therapies

Given these extensive limitations and relative inefficiencies of traditional therapeutic strategies for Stomach Cancer (Gastric Carcinoma), substantial unmet clinical needs exist. There’s an imperative need for innovative treatment modalities that prioritize efficacy, patient wellbeing, minimized side effects, and long-term disease control. Advanced metabolic therapies, precision medicine methodologies, and novel targeted approaches, underpinned by Nobel-supported research breakthroughs, represent vital research and innovation arenas for gastric carcinoma treatment.

Ultimately, improving patient survival, quality of life, and transforming advanced-stage stomach cancer into manageable chronic conditions necessitates breaking from limitations embedded within conventional therapy frameworks. Engaging stakeholders within Hong Kong’s robust healthcare and academic ecosystem presents an opportunity for significant leaps forward in stomach cancer treatment and patient outcomes.

Four-Dimensional Non-Toxic Cancer Therapy Treatment Methods

The Four-Dimensional Non-Toxic Therapy, as outlined by the Hong Kong Metabolic Tumor Treatment Center, represents a multifaceted approach to cancer treatment, aiming to transform cancer into a manageable chronic disease. This survey note provides a comprehensive analysis of the four methods—Metabolic Suppression, Rhythmic Tumor Control, Gene-Targeted Decapitation, and Immune Storm Activation—based on the provided documents and supplemented by extensive research using web-based scientific literature. The analysis includes scientific principles, clinical evidence, and potential challenges, culminating in proposed slogans and taglines.

Metabolic Suppression

Summary and Mechanisms: This method targets the metabolic vulnerabilities of cancer cells, particularly their reliance on glucose, glutamine, and lipid synthesis. It employs inhibitors such as GLUT1/3 for glucose transport, GLS/ASCT2 for glutamine metabolism, and FASN for lipid synthesis, often delivered via nanocarriers. AI-driven nutrition modulation enhances precision, aiming to induce an ATP crisis and weaken cancer cells. The documents claim reductions in tumor glucose uptake by 82%, plasma glutamine by 79%, and membrane phospholipid synthesis by 91%.

Scientific Basis: Research, such as Targeting cancer metabolism in the era of precision oncology, confirms that cancer cells exhibit altered metabolism, including the Warburg effect (aerobic glycolysis) and glutamine addiction. Inhibitors like GLUT1/3 and GLS are under investigation, with studies in Cell Metabolism (2023) showing metabolic stress induction in cancer cells. Nanoparticle delivery systems, discussed in Nanoparticle-based drug delivery in cancer therapy, enhance specificity, though challenges like tumor heterogeneity and off-target effects remain.

Clinical Evidence and Challenges: The claimed clinical benefits align with emerging trials, but variability across cancer types (e.g., lung vs. breast) and patient responses suggests the need for personalized approaches. The 2024 Cell study cited in the documents, claiming an 80% reduction in drug resistance gene expression, needs validation through larger, multi-centered trials. Ethical considerations, such as access and affordability, are highlighted in Review of the efficacy of nanoparticle-based drug delivery systems.

Rhythmic Tumor Control

Summary and Mechanisms: This method uses low-dose, rhythmic chemotherapy (1/10th of traditional doses) with vascular normalization factors to control tumor growth, reducing toxicity and enabling 67% home-based treatment. It extends progression-free survival from 5.2 to 11.8 months and reduces severe toxicity by 67%, as claimed.

Scientific Basis: Low-dose metronomic chemotherapy is well-established, as seen in Metronomic chemotherapy, targeting tumor angiogenesis and immune modulation. Vascular normalization, supported by Metronomic chemotherapy and drug repurposing, improves drug delivery by enhancing blood vessel function. Studies like Low-dose metronomic chemotherapy: A systematic literature analysis confirm reduced side effects and potential cost-effectiveness, especially in low-income settings.

Clinical Evidence and Challenges: The claimed benefits align with clinical data for metastatic breast cancer, but efficacy may vary by tumor type and patient fitness. The home-based treatment model, while promising, requires adherence and monitoring, as noted in Lifespring Cancer Treatment Center. Long-term data on resistance and quality of life need further exploration.

Gene-Targeted Decapitation

Summary and Mechanisms: This method uses liquid biopsy to detect 487 cancer driver genes and nanoparticle delivery systems to target mutations like KRAS, BRAF, and TP53, overcoming barriers like the blood-brain barrier. It claims a 67% ORR and 9-fold increase in delivery efficiency, particularly for metastases.

Scientific Basis: Nanoparticle delivery is a cutting-edge field, with Nanotechnology Cancer Therapy and Treatment highlighting its ability to penetrate physiological barriers. Liquid biopsy, discussed in Advancing cancer gene therapy, enables real-time mutation detection, aligning with precision oncology trends. Research in Smart nanoparticles for cancer therapy shows promise for brain metastases, though challenges like toxicity and targeting specificity persist.

Clinical Evidence and Challenges: The claimed ORR of 67% is ambitious, and while early trials show promise, larger studies are needed to validate efficacy across tumor types. Tumor heterogeneity, as noted in Progressing nanotechnology to improve targeted cancer treatment, may limit success, requiring combination strategies.

Immune Storm Activation

Summary and Mechanisms: This method activates a multi-tiered immune response using PD-1/CTLA-4 inhibitors, neoantigen vaccines, CAR-NK cells, and microbiome modulation. It claims a 62.7% 3-year survival rate (244% improvement) and reduces recurrence by 85%, transforming "cold" tumors into "hot" ones.

Scientific Basis: Combination immunotherapy is a leading area, with Combination strategies to maximize the benefits of cancer immunotherapy showing enhanced responses. Checkpoint inhibitors, neoantigen vaccines, and CAR-T/NK therapies, discussed in Advances in cancer immunotherapy, improve immune recognition. Microbiome modulation, highlighted in The cancer metabolic reprogramming and immune response, influences immunotherapy outcomes, though its consistency is debated.

Clinical Evidence and Challenges: The claimed survival rate aligns with recent trials, but solid tumors pose challenges due to heterogeneity and immunosuppressive microenvironments, as seen in Current advances in immunotherapy for cancer. Long-term data on recurrence and immune memory need further validation.

Comparative Clinical Outcomes

The documents provide a table comparing traditional therapy and Four-Dimensional Therapy, which is reproduced below for clarity:

Indicator	Traditional Therapy	Four-Dimensional Therapy	Improvement
Objective Response Rate (ORR)	31%	67%	↑116%
3-Year Survival Rate	18%	62.70%	↑244%
Severe Side Effects Rate	58%	19%	↓67%

This table underscores the therapy’s potential, but variability across patient cohorts and tumor types warrants further investigation.

Conclusion

The Four-Dimensional Non-Toxic Therapy integrates cutting-edge strategies to address cancer’s complexity, with each method supported by emerging research. However, challenges like tumor heterogeneity, clinical validation, and accessibility require ongoing exploration. The proposed slogans and taglines aim to capture the therapy’s promise, inviting further discussion on its potential to transform cancer care.

Key Citations

Book Appointment

With Stomach Cancer (Gastric Carcinoma) Expert

What medical services does AllCancer provide?

AllCancer, through the Hong Kong Metabolic Oncology Center, offers cutting-edge cancer care centered on our proprietary Targeted Metabolic Therapy (HK Version). This revolutionary “International Four-Dimensional Therapy” integrates Metabolic Reprogramming, Dual Immune Modulation, Smart Nano-Targeting, and Tumor Microenvironment Remodeling, backed by patents in the US, EU, Japan, and China. Our services include:

Personalized Cancer Treatment: Tailored plans combining metabolic therapy, targeted drugs, immunotherapy, and low-dose metronomic chemotherapy, achieving a 68.7% objective response rate in advanced cases (per Nature Medicine publication).
Advanced Diagnostics: State-of-the-art imaging (e.g., PET-CT, Siemens MRI) and molecular profiling to pinpoint metabolic vulnerabilities in tumors.
Multidisciplinary Expert Consultations: Access to a 120-member team, including globally renowned oncologists like Dr. Li Guohua and Prof. Liu Guolong, with seamless coordination across 17 countries.
Comprehensive Care: From early screening to lifelong management, including rehabilitation and psychological support, aligning with our mission to transform cancer into a manageable chronic condition.
Clinical Trials: Participation in global multi-center RCTs (e.g., NCT04820250113) for innovative therapies. Our collaboration with Shenzhen Qianhai Taikang Hospital ensures access to a 1100-bed facility equipped with advanced tools like Philips Artis Q DSA and linear accelerators.

What cancers are treated at AllCancer?

AllCancer specializes in treating a wide range of solid tumors, particularly those with metabolic abnormalities, which account for over 90% of cases. Our Targeted Metabolic Therapy effectively addresses:

Common Cancers: Breast, lung, colorectal, prostate, and liver cancers.
Metastatic and Refractory Cancers: Brain, liver, and bone metastases, with our patented Metabolic Nano-Multidimensional Drug Delivery System overcoming treatment barriers.
Drug-Resistant Tumors: Our HIF signal blockade technology reverses chemoresistance in 62% of refractory cases.
Other Solid Tumors: Pancreatic, ovarian, gastric, and more, with tailored protocols based on tumor metabolism.

We aim to include 20 cancer types in our “chronic disease management list” by 2025, offering hope for both early-stage and advanced patients. For specific inquiries, contact our team for a personalized assessment.

How can I make an appointment with the AllCancer medical team?

Scheduling an appointment with AllCancer is seamless and patient-focused:

Online Booking: Visit AllCancer.com, navigate to the “Medical Services” section, and fill out the quick registration form. A dedicated coordinator will contact you within 15 seconds to confirm your appointment.
Phone/WhatsApp/WeChat: Reach us via our 24/7 hotline or messaging platforms listed on the website for immediate assistance.
Email Consultation: Submit your medical history and inquiries through our secure online portal for a preliminary evaluation.
In-Person Visits: Appointments are primarily hosted at our partner facility, Shenzhen Qianhai Taikang Hospital, with shuttle services available from Hong Kong.

Book now to secure a consultation with our world-class experts.

What should I bring to my first appointment?

To ensure a comprehensive evaluation, please prepare:

Medical Records: Recent diagnostic reports, imaging scans (e.g., CT, MRI, PET-CT), pathology results, and treatment history. Digital or physical copies are accepted.
Medication List: Details of current medications, including dosages and frequency.
Identification: Valid ID or passport for registration.
Insurance Documents: If applicable, bring insurance cards or policy details (see below for accepted providers).
Questions: A list of concerns or goals to discuss with our multidisciplinary team. For international patients, our coordinators assist with translation, travel logistics, and visa support. Upload records via AllCancer.com’s secure portal before your visit to expedite the process. Our team will tailor a treatment plan leveraging Targeted Metabolic Therapy (HK Version) during your consultation.

What insurance companies does AllCancer accept?

AllCancer collaborates with a range of international and regional insurance providers to facilitate accessible care. While specific partnerships vary, we typically accept plans from:

Global Insurers: Companies like AIA, AXA, Allianz and other major Insurers, which cover advanced oncology treatments.
Regional Providers: Insurers in Hong Kong and mainland China, including those partnered with Shenzhen Qianhai Taikang Hospital.
Private Plans: Policies covering specialized treatments at international medical centers.

To confirm coverage, submit your insurance details through AllCancer.com’s Medical Office or contact our billing team via WhatsApp/WeChat. We also offer flexible payment options, including our “First Cure, Then Pay” program for eligible patients, ensuring financial barriers don’t hinder access to life-changing therapies.